VetSheet

Proxymetacaine

Proxymetacaine hydrochloride

Local Anaesthetic (Ophthalmic)TopicalDogsCats

Also known as: Alcaine ยท Minims Proxymetacaine ยท Ophthaine ยท Proxymetacaine hydrochloride ยท Proparacaine hydrochloride

Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference

1-2 drops/eyetopicalยท PRNยท Single application (or serial for depth)

Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.

Dosing by species

๐ŸŒŽ NA โ€” North America๐ŸŒ EU โ€” Europe

Dogs

IndicationDoseRouteFrequencyDurationRegion
Ocular surface anaesthesia1-2 drops/eyetopicalPRNSingle application (or serial for depth)๐ŸŒ EU
Aural/nasal anaesthesia5-10 drops/ear or nosetopicalq5-10minMaximum 3 doses if used intranasally๐ŸŒ EU
  • Ocular surface anaesthesia: Maximal effect at 15 min, duration 45-55 min.

Cats

IndicationDoseRouteFrequencyDurationRegion
Ocular surface anaesthesia1-2 drops/eyetopicalPRNSingle application๐ŸŒ EU
  • Ocular surface anaesthesia: Maximal effect at 15 min, duration 25 min.

Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.

Recording this consult? VetSheet's AI writes the drug, dose and duration straight into a structured visit note.See how VetSheet works

Overview

Proxymetacaine (also known as proparacaine) is a rapid-acting topical local anaesthetic used primarily on the ocular surface (cornea and conjunctival sac), as well as the external auditory meatus and nares. It acts rapidly (within 1 minute) and provides anaesthesia for 25-55 minutes depending on the species.

โ€‹Clinical Warning:โ€‹ All topical anaesthetics are toxic to the corneal epithelium. Repeated application delays the healing of ulcers and can lead to severe corneal melting. โ€‹Never dispense for home use as a therapeutic analgesic.โ€‹

โ€‹Clinical Pearl:โ€‹ Serial application increases both the duration and depth of anaesthesia. Because topical anaesthetics block reflex tear production, they should not be applied prior to performing a Schirmer tear test.

Mechanism of action

Local anaesthetic action is dependent on the reversible blockade of voltage-gated sodium channels โ†’ prevents the influx of sodium ions โ†’ inhibits the propagation of an action potential along the nerve fibre.

Sensory nerve fibres are blocked before motor nerve fibres, allowing a selective sensory blockade at low doses.

Safety & warnings

Contraindications

  • Therapeutic use (e.g., home pain management)
  • Application prior to a Schirmer tear test

Adverse effects

  • Conjunctival hyperaemia (common)
  • Local irritation / chemosis (occasional)
  • Corneal epithelial toxicity
  • Delayed corneal ulcer healing

Precautions

โ€‹Corneal Toxicity:โ€‹ Repeated use causes severe epithelial toxicity and delays ulcer healing. Must only be used for diagnostic or minor surgical procedures in a clinical setting. โ€‹Diagnostic Interference:โ€‹ Do not use before a Schirmer tear test as it abolishes reflex tearing.

Monitoring

  • Corneal integrity (fluorescein staining if damage is suspected)
  • Resolution of anaesthesia (protect the eye from trauma while numb)

Pharmacokinetics

Absorption

Rapid onset (< 1 minute) following topical application to mucous membranes.

Distribution

Acts locally at the site of application (cornea, conjunctiva, nasal mucosa, ear canal).

Metabolism

Ester-type local anaesthetics are generally hydrolyzed by plasma pseudocholinesterases and esterases in the tissue.

Elimination

Metabolites are primarily excreted via the kidneys.

Overdose

Overdosage via repeated topical application leads to severe corneal toxicity, epithelial sloughing, delayed healing of ulcers, and potentially corneal melting. Systemic toxicity is rare with standard ophthalmic use but could theoretically cause CNS excitation followed by depression and cardiovascular collapse if massive amounts are absorbed through mucous membranes.

Available products

Formulations

  • 0.5% ophthalmic solution (single-use vials)

Veterinary

  • Proxymetacaine 0.5% single-use vials

Human-labeled

  • Minims Proxymetacaine Hydrochloride 0.5% eye drops
  • Alcaine 0.5% ophthalmic solution

Regulatory status

United Statesโœ“ ApprovedPrescription onlyFDA/CVM
๐Ÿ• Dogs๐Ÿˆ Cats

Commonly known as Proparacaine in the US.

European Unionโœ“ ApprovedPrescription onlyEMA
๐Ÿ• Dogs๐Ÿˆ Cats

POM (Prescription Only Medicine)

United Kingdomโœ“ ApprovedPrescription onlyVMD
๐Ÿ• Dogs๐Ÿˆ Cats

POM-V

No regulatory data for: ๐Ÿ‡ญ๐Ÿ‡ฐ HK ยท ๐Ÿ‡น๐Ÿ‡ผ TW ยท ๐Ÿ‡ฏ๐Ÿ‡ต JP ยท ๐Ÿ‡ฐ๐Ÿ‡ท KR ยท ๐Ÿ‡ฆ๐Ÿ‡บ AU

Storage & stability

Store in a refrigerator (2-8ยฐC) and protect from light. Efficacy is reduced if stored at room temperature for >2 weeks.

Client information

This medication is for in-clinic veterinary use only to facilitate eye examinations or minor procedures.

โ€‹Warning:โ€‹ It is never prescribed for home use. Repeated use of numbing eye drops will cause severe, potentially blinding damage to the surface of the eye (corneal ulcers). While your pet's eye is numb after the vet visit, prevent them from rubbing or scratching it.

VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturerโ€™s current label.